Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UNITED THERAPEUTICS (UTHR) Other Accumulated Expenses: 2009-2024

Historic Other Accumulated Expenses for UNITED THERAPEUTICS (UTHR) over the last 16 years, with Dec 2024 value amounting to $93.6 million.

  • UNITED THERAPEUTICS's Other Accumulated Expenses fell 2.25% to $78.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $78.3 million, marking a year-over-year decrease of 2.25%. This contributed to the annual value of $93.6 million for FY2024, which is 31.83% up from last year.
  • Latest data reveals that UNITED THERAPEUTICS reported Other Accumulated Expenses of $93.6 million as of FY2024, which was up 31.83% from $71.0 million recorded in FY2023.
  • In the past 5 years, UNITED THERAPEUTICS's Other Accumulated Expenses registered a high of $93.6 million during FY2024, and its lowest value of $28.4 million during FY2021.
  • Moreover, its 3-year median value for Other Accumulated Expenses was $71.0 million (2023), whereas its average is $65.7 million.
  • Per our database at Business Quant, UNITED THERAPEUTICS's Other Accumulated Expenses dropped by 28.10% in 2021 and then spiked by 118.46% in 2023.
  • Over the past 5 years, UNITED THERAPEUTICS's Other Accumulated Expenses (Yearly) stood at $39.5 million in 2020, then declined by 28.10% to $28.4 million in 2021, then climbed by 14.44% to $32.5 million in 2022, then spiked by 118.46% to $71.0 million in 2023, then skyrocketed by 31.83% to $93.6 million in 2024.